Previous close | 34.39 |
Open | 34.10 |
Bid | 34.42 x 200 |
Ask | 34.50 x 100 |
Day's range | 34.10 - 34.48 |
52-week range | 14.31 - 39.79 |
Volume | |
Avg. volume | 453,826 |
Market cap | 1.632B |
Beta (5Y monthly) | 2.91 |
PE ratio (TTM) | N/A |
EPS (TTM) | -5.12 |
Earnings date | 05 Aug 2024 - 09 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 35.50 |
Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that it has set a record date of May 17, 2024 (the "Record Date") for the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. ("SpinCo"), to holders of shares of the Company's common stock on a pro rata basis (the "Spin-Off").
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -61.68% and 1,534%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with three clinical programs in development and a strong emerging pipeline, today reported financial results for the fourth quarter and fiscal year 2023.